Nucleic acid reagent, reagent kit, system and method for detecting escherichia coli and klebsiella pneumoniae and toxicity and reverse tolerance of escherichia coli and klebsiella pneumoniae
A technology for Klebsiella pneumoniae and Escherichia coli, which is applied in biochemical equipment and methods, microbiological determination/inspection, DNA/RNA fragments, etc., can solve the problems of time-consuming, laborious detection, poor detection accuracy, and low detection sensitivity , achieve high conservatism and specificity, and save time
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0075] Example 1 Detection method and detection result judgment
[0076] 1. Synthesis of primers and probes
[0077] According to the primer sequence shown in Table 1 and the probe sequence shown in Table 2, sequence synthesis was performed. In the probe, FAM is 6-carboxyfluorescein, HEX is hexachloro-6-methylfluorescein, CY5 is 5H-indocyanine, ROX is 6-carboxy-X-rhodamine, and VIC is a dye purchased from ABI , BHQ1, BHQ2 and BHQ3 are quenching groups.
[0078] Table 1
[0079]
[0080]
[0081] Table 2
[0082] Detection target Probe sequence Probe sequence SEQ ID NO Klebsiella pneumoniae KP-P ROX-cctacaccagctccgaccgtaccaa-BHQ229 Escherichia Coli uidA-P CY5-tcggcatccggtcagtggcagt-BHQ330 iroB iroB-P FAM-agtctcggcaccgtcaaacc-BHQ131 magA magA-P VIC-tcgccgcaaatacgagaagtgtagt-BHQ132 peg344 peg344-P CY5-cctccgtgatgaggatgaacgaaagtgaag-BHQ333 iucA iucA-P CY5-ctatactgcgccaccagccgcgacatgat-BHQ334 rmpA rmpA-P VIC-cagggaaatggggagggtacaaaat-BHQ135 rmpA2 rmpA2-P FAM-cagggaaatgggatggtta...
Example Embodiment
[0104] Example 2 Verification of the lowest detection limit
[0105] The Escherichia coli species gene, Klebsiella pneumoniae species gene, iroB virulence factor, magA virulence factor, peg344 virulence factor, iucA virulence factor, rmpA virulence factor, rmpA2 virulence factor, KPC The gene fragments of drug resistance gene, NDM drug resistance gene, IMP drug resistance gene, VIM drug resistance gene, and OXA-48 drug resistance gene were connected to the PUC57 vector and sequenced and checked to obtain each recombinant plasmid. The construction of the above recombinant plasmids and the sequencing and proofreading work were completed by Shanghai Shenggong Biotechnology Company.
[0106] The concentration of the recombinant plasmid containing the above target gene fragments was quantified to 10 10 Copy / μL, and perform serial dilutions to obtain a concentration of 10 5 Copy / μL, 10 4 Copy / μ, 10 3 Copy / μL, 10 2 Copy / μL, 10 1 Copy / μL, 10 0 Copy / μL of test sample.
[0107] According to t...
Example Embodiment
[0109] Example 3 Specificity verification
[0110] Select Enterobacter cloacae (purchased from China Medical Culture Collection, number 45301), Serratia marcescens (purchased from China Medical Culture Collection, number 41002), Salmonella paratyphi A (purchased from China Medical Culture Collection Center, No. 50001), Salmonella Paratyphi B (purchased from China Medical Culture Collection, No. 50004), Bacillus mycoides (purchased from China Medical Culture Collection, No. 32012), Wei Bacillus spp (purchased from China Medical Culture Collection, number 32011), Bacillus subtilis (purchased from China Medical Culture Collection, number 32041), Staphylococcus aureus (purchased from China Medical Culture Collection, No. 26003), Vibrio parahaemolyticus (purchased from the Chinese Medical Culture Collection, No. 21617), Listeria monocytogenes (purchased from the Chinese Medical Culture Collection, No. 54002), Cholera Vibrio (purchased from China Medical Culture Collection, number 110...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap